ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: June 2025
|
Report Code: QYRE-Auto-34B8760
Home | Market Reports | Health| Men s Health
Global Benign Prostatic Hyperplasia BPH Drugs Market Outlook 2022
BUY CHAPTERS

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-34B8760
Report
June 2025
Pages:156
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Abbott
Allergan plc
TEVA
Mylan NV
Novartis
Merck
Pfizer Inc
Astellas Pharma
Eli Lilly
GlaxoSmithKline PLC
Sanofi

Benign Prostatic Hyperplasia (BPH) Drugs Market Size

In 2024, the global market size of Benign Prostatic Hyperplasia (BPH) Drugs was estimated to be worth US$ 3555 million and is forecast to reach approximately US$ 4448 million by 2031 with a CAGR of 3.3% during the forecast period 2025-2031.

Benign Prostatic Hyperplasia (BPH) Drugs Market

Benign Prostatic Hyperplasia (BPH) Drugs Market

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man"s life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.
The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.

Scope of Benign Prostatic Hyperplasia (BPH) Drugs Market Report

Report Metric Details
Report Name Benign Prostatic Hyperplasia (BPH) Drugs Market
Forecasted market size in 2031 approximately US$ 4448 million
CAGR 3.3%
Forecasted years 2025 - 2031
Segment by Type
  • Alpha-Blocker
  • Phosphodiesterase Type-5 Inhibitors
  • Others
Segment by Application
  • Hospitals
  • Drugstores
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA, Mylan, Novartis, Merck
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Benign Prostatic Hyperplasia (BPH) Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
  • Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion.

FAQ for this report

What is the Benign Prostatic Hyperplasia (BPH) Drugs Market size in 2031?

Ans: The Benign Prostatic Hyperplasia (BPH) Drugs Market size in 2031 will be approximately US$ 4448 million.

What is the Benign Prostatic Hyperplasia (BPH) Drugs Market share by region?

Ans: North America is the largest consumption place, with a consumption market share nearly 38% in 2019.

Who are the main players in the Benign Prostatic Hyperplasia (BPH) Drugs Market report?

Ans: The main players in the Benign Prostatic Hyperplasia (BPH) Drugs Market are Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA, Mylan, Novartis, Merck

What are the Application segmentation covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report?

Ans: The Applications covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report are Hospitals, Drugstores, Others

What are the Type segmentation covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report?

Ans: The Types covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report are Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors, Others

1 Study Coverage
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2031
2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2031
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2024 Versus 2031
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2031)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2020-2025
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2026-2031)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2031)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2020-2025
2.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2026-2031)
2.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2031)
3.1.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2020-2031)
3.1.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2031)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2031)
3.1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2031)
3.1.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2020-2031)
3.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2031)
3.2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2020-2031)
3.2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2031)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2031)
3.2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2031)
3.2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2031)
3.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Alpha-Blocker of Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application
3.3.2 Phosphodiesterase Type-5 Inhibitors of Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application
3.3.3 Others of Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application
4 Global Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturers
4.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Sales (2020-2025)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2020-2025)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Revenue (2020-2025)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2020-2025)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturer (2020-2025)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Covered: Ranking by Revenue
4.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Product Type
4.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
4.5.3 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type and Application
4.5.4 Alpha-Blocker Market Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer
4.5.5 Phosphodiesterase Type-5 Inhibitors Market Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer
4.5.6 Others Market Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Eli Lilly
5.1.1 Eli Lilly Company Information
5.1.2 Eli Lilly Description, Business Overview
5.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.1.6 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.1.7 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.1.8 Eli Lilly Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Company Information
5.2.2 GlaxoSmithKline Description, Business Overview
5.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.2.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.2.6 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.2.7 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.2.8 GlaxoSmithKline Recent Developments
5.3 Astellas Pharma
5.3.1 Astellas Pharma Company Information
5.3.2 Astellas Pharma Description, Business Overview
5.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.3.6 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.3.7 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.3.8 Astellas Pharma Recent Developments
5.4 Sanofi
5.4.1 Sanofi Company Information
5.4.2 Sanofi Description, Business Overview
5.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.4.6 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.4.7 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.4.8 Sanofi Recent Developments
5.5 Pfizer
5.5.1 Pfizer Company Information
5.5.2 Pfizer Description, Business Overview
5.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.5.6 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.5.7 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.5.8 Pfizer Recent Developments
5.6 Abbott
5.6.1 Abbott Company Information
5.6.2 Abbott Description, Business Overview
5.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.6.6 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.6.7 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.6.8 Abbott Recent Developments
5.7 Allergan
5.7.1 Allergan Company Information
5.7.2 Allergan Description, Business Overview
5.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.7.6 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.7.7 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.7.8 Allergan Recent Developments
5.8 TEVA
5.8.1 TEVA Company Information
5.8.2 TEVA Description, Business Overview
5.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.8.5 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.8.6 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.8.7 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.8.8 TEVA Recent Developments
5.9 Mylan
5.9.1 Mylan Company Information
5.9.2 Mylan Description, Business Overview
5.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.9.5 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.9.6 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.9.7 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.9.8 Mylan Recent Developments
5.10 Novartis
5.10.1 Novartis Company Information
5.10.2 Novartis Description, Business Overview
5.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.10.6 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.10.7 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.10.8 Novartis Recent Developments
5.11 Merck
5.11.1 Merck Company Information
5.11.2 Merck Description, Business Overview
5.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
5.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product in 2024
5.11.6 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application in 2024
5.11.7 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Area in 2024
5.11.8 Merck Recent Developments
6 North America
6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2020-2031
6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
6.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
6.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
6.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region
7.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2031)
7.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2031)
7.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
7.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
8 Europe
8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2020-2031
8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
8.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
8.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
8.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2020-2031
9.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
9.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
9.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
9.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
9.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
10.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
10.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
10.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
10.4 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Benign Prostatic Hyperplasia (BPH) Drugs Supply Chain Analysis
11.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials and Upstream Suppliers
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Clients Analysis
11.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channel and Sales Model Analysis
11.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
12 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
12.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Abbott
Allergan plc
TEVA
Mylan NV
Novartis
Merck
Pfizer Inc
Astellas Pharma
Eli Lilly
GlaxoSmithKline PLC
Sanofi
List of Tables
 Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025) & (M Units)
 Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2026-2031) & (M Units)
 Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2020-2025) & (M Units)
 Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2026-2031) & (M Units)
 Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2020-2025) & (M Units)
 Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2026-2031) & (M Units)
 Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2020-2025) & (M Units)
 Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturer (2020-2025)
 Table 18. Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2020-2025) & (US$ Million)
 Table 19. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturer (2020-2025)
 Table 20. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2020-2025) & (US$/Unit)
 Table 21. Ranking of Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Revenue (US$ Million) in 2024
 Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2024)
 Table 24. Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
 Table 25. Date of International Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
 Table 26. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type and Application
 Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 28. Eli Lilly Company Information
 Table 29. Eli Lilly Description and Business Overview
 Table 30. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 31. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 32. Eli Lilly Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 33. Eli Lilly Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 34. Eli Lilly Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 35. Eli Lilly Recent Developments
 Table 36. GlaxoSmithKline Company Information
 Table 37. GlaxoSmithKline Description and Business Overview
 Table 38. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 39. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 40. GlaxoSmithKline Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 41. GlaxoSmithKline Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 42. GlaxoSmithKline Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 43. GlaxoSmithKline Recent Developments
 Table 44. Astellas Pharma Company Information
 Table 45. Astellas Pharma Description and Business Overview
 Table 46. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 47. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 48. Astellas Pharma Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 49. Astellas Pharma Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 50. Astellas Pharma Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 51. Astellas Pharma Recent Developments
 Table 52. Sanofi Company Information
 Table 53. Sanofi Description and Business Overview
 Table 54. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 55. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 56. Sanofi Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 57. Sanofi Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 58. Sanofi Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 59. Sanofi Recent Developments
 Table 60. Pfizer Company Information
 Table 61. Pfizer Description and Business Overview
 Table 62. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 63. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 64. Pfizer Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 65. Pfizer Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 66. Pfizer Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 67. Pfizer Recent Developments
 Table 68. Abbott Company Information
 Table 69. Abbott Description and Business Overview
 Table 70. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 71. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Abbott Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 73. Abbott Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 74. Abbott Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 75. Abbott Recent Developments
 Table 76. Allergan Company Information
 Table 77. Allergan Description and Business Overview
 Table 78. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 79. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. Allergan Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 81. Allergan Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 82. Allergan Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 83. Allergan Recent Developments
 Table 84. TEVA Company Information
 Table 85. TEVA Description and Business Overview
 Table 86. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 87. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. TEVA Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 89. TEVA Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 90. TEVA Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 91. TEVA Recent Developments
 Table 92. Mylan Company Information
 Table 93. Mylan Description and Business Overview
 Table 94. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 95. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 96. Mylan Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 97. Mylan Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 98. Mylan Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 99. Mylan Recent Developments
 Table 100. Novartis Company Information
 Table 101. Novartis Description and Business Overview
 Table 102. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 103. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Novartis Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 105. Novartis Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 106. Novartis Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 107. Novartis Recent Developments
 Table 108. Merck Company Information
 Table 109. Merck Description and Business Overview
 Table 110. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
 Table 111. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 112. Merck Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Product in 2024
 Table 113. Merck Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2024
 Table 114. Merck Sales Proportion of Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Area in 2024
 Table 115. Merck Recent Developments
 Table 116. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
 Table 117. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2026-2031) & (M Units)
 Table 118. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 119. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 120. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
 Table 121. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
 Table 122. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025) & (M Units)
 Table 123. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2026-2031) & (M Units)
 Table 124. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 125. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 126. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
 Table 127. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
 Table 128. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
 Table 129. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2026-2031) & (M Units)
 Table 130. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 131. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 132. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
 Table 133. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
 Table 134. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
 Table 135. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2026-2031) & (M Units)
 Table 136. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 137. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 138. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
 Table 139. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
 Table 140. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) & (M Units)
 Table 141. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2026-2031) & (M Units)
 Table 142. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 143. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 144. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
 Table 145. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
 Table 146. Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials, Industry Status and Trend
 Table 147. Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials and Upstream Suppliers
 Table 148. Benign Prostatic Hyperplasia (BPH) Drugs Clients Status and Trend
 Table 149. Benign Prostatic Hyperplasia (BPH) Drugs Typical Clients
 Table 150. Benign Prostatic Hyperplasia (BPH) Drugs Distributors
 Table 151. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
 Table 152. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
 Table 153. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
 Table 154. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
 Table 155. Research Programs/Design for This Report
 Table 156. Key Data Information from Secondary Sources
 Table 157. Key Data Information from Primary Sources
 Table 158. QYR Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
 Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2024 & 2031
 Figure 4. Alpha-Blocker Product Picture
 Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2024 & 2031
 Figure 9. Hospitals
 Figure 10. Drugstores
 Figure 11. Others
 Figure 12. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
 Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2020-2031 (US$ Million)
 Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2020-2031 (M Units)
 Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2020-2031)
 Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2031)
 Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2020-2031)
 Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2020-2031)
 Figure 20. Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Type (2020-2025) & (US$/Unit)
 Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2020-2031)
 Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2020-2031)
 Figure 23. Benign Prostatic Hyperplasia (BPH) Drugs Average Selling Price (ASP) by Application (2020-2025) & (US$/Unit)
 Figure 24. Alpha-Blocker of Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application, 2024 VS 2031
 Figure 25. Phosphodiesterase Type-5 Inhibitors of Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application, 2024 VS 2031
 Figure 26. Others of Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application, 2024 VS 2031
 Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturer in 2024
 Figure 28. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 29. Alpha-Blocker Market Sales Proportion by Manufacturer in 2024
 Figure 30. Phosphodiesterase Type-5 Inhibitors Market Sales Proportion by Manufacturer in 2024
 Figure 31. Others Market Sales Proportion by Manufacturer in 2024
 Figure 32. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2031 (US$ Million)
 Figure 33. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
 Figure 34. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
 Figure 35. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2020-2031 (US$ Million)
 Figure 36. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2031)
 Figure 37. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2031)
 Figure 38. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
 Figure 39. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
 Figure 40. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 41. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2031)
 Figure 42. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2031)
 Figure 43. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
 Figure 44. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
 Figure 45. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 46. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)
 Figure 48. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
 Figure 49. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
 Figure 50. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 51. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2031)
 Figure 53. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
 Figure 54. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
 Figure 55. Benign Prostatic Hyperplasia (BPH) Drugs Supply Chain (Upstream and Downstream Market)
 Figure 56. Global Production Market Share of Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials by Region in 2024
 Figure 57. Benign Prostatic Hyperplasia (BPH) Drugs Distribution Channels
 Figure 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Oral Drugs for Benign Prostatic Hyperplasia Market Research Report 2025
Benign Prostatic Hyperplasia BPH Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benign Prostatic Hyperplasia BPH Treatment Market Research Report 2024
BPH Treatment Equipment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benign Prostatic Hypertrophy Medication Market Research Report 2024
Benign Prostatic Hyperplasia BPH Laser Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Benign Prostatic Hyperplasia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Benign Prostatic Hyperplasia BPH Treatment Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Laser Benign Prostatic Hyperplasia BPH Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Benign Prostatic Hyperplasia Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benign Prostate Hyperplasia Drugs Market Insights Forecast to 2030
Medicine Treat BPH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prostate Cancer Medicine Market Insights Forecast to 2030
Global Benign Prostatic Hyperplasia Equipment Market Research Report 2025
Global Benign Prostatic Hyperplasia Treatment Market Insights Forecast to 2030
Global Prostate Cancer Market Insights Forecast to 2030
Benign Prostatic Hyperplasia Treatment Equipments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prostate Cancer Diagnostics Market Research Report 2025
Laser Treatment Devices for BPH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Transurethral Resection Of The Prostate Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions